Sugi Predict
/ Targets
/ SMARCE1
Top predicted compounds (top 20 by supporting neighbours, then confidence)
| Compound | Confidence | Supporting neighbours |
|---|
Clinical trials — most relevant to SMARCE1 by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01) |
PHASE3 | RECRUITING |
| Cornelia De Lange Syndrome: Assessing Positive Effects of Lithium Treatment |
PHASE2/PHASE3 | RECRUITING |
| PARP Inhibitor With CDK4/ 6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer |
PHASE3 | ACTIVE_NOT_RECRUITING |
| A Phase II Study of Anlotinib and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Lung Cancer. |
PHASE2 | NOT_YET_RECRUITING |
| Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma |
PHASE2 | RECRUITING |
| Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) |
PHASE2 | COMPLETED |
| SMARCA4/2 Inhibitor for POU2F3-Positive SCLC |
PHASE2 | NOT_YET_RECRUITING |
| A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma |
PHASE2 | COMPLETED |
| Efficacy and Safety of the Valemetostat in Patients With Selected Solid Tumors. |
PHASE2 | RECRUITING |
| Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors |
PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING |
| Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) |
PHASE2 | ACTIVE_NOT_RECRUITING |
| PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer |
PHASE2 | RECRUITING |
| A Phase II Study of QL1706 and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Non-Small Cell Lung Cancer. |
PHASE2 | NOT_YET_RECRUITING |
| Phase II Trial of Sacituzumab Tirumotecan in Patients With SMARCB1-Deficient Renal Medullary Carcinoma |
PHASE2 | NOT_YET_RECRUITING |
| Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors |
PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING |
| Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer |
PHASE2 | ACTIVE_NOT_RECRUITING |
| An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy |
PHASE2 | COMPLETED |
| Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers |
PHASE1/PHASE2 | COMPLETED |
| Testing of the Addition of a New Anti-cancer Drug, Molibresib, to Chemotherapy Treatment (Etoposide and Cisplatin) for Patients With NUT Carcinoma |
PHASE1/PHASE2 | WITHDRAWN |
| Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure |
PHASE2 | COMPLETED |
| PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation |
PHASE1 | COMPLETED |
| Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer |
PHASE1 | RECRUITING |
| Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients |
nan | RECRUITING |
| Efficacy and Safety Analysis of First-Line ABCP Therapy in Advanced SMARCA4-Mutated NSCLC |
nan | NOT_YET_RECRUITING |
| Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics |
nan | UNKNOWN |
| Implementation of FEES in Spinal Muscle Atrophy |
nan | COMPLETED |
| Next-Generation Sequencing-based Germline and Somatic Genetic Testing in Triple-negative Breast Cancer |
nan | UNKNOWN |
| Motor Development and Orthoses in Spinal Muscular Atrophy (SMA) |
nan | COMPLETED |
| PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia |
nan | UNKNOWN |
| Palliative Care in Spinal Muscular Atrophy (SMA) 1 |
nan | COMPLETED |
Related proteins — ESM-2 sequence neighbours (a SMARCE1 binder may also engage these)